Izzy Lubarsky

Cooley advised Thirty Madison, a specialty healthcare company offering high-quality virtual specialized care for patients experiencing a range of conditions, on its definitive agreement to be acquired by Remedy Meds in an all-stock transaction valued in excess of $500 million.

Cooley advised Contentsquare, an all-in-one experience intelligence platform, on its definitive agreement to acquire Loris AI, a conversation intelligence platform, to give business leaders a deeper, more accurate view of the full customer journey – from click to conversation.

Cooley advised Datadog (Nasdaq: DDOG), a monitoring and security platform for cloud applications, on its acquisition of Eppo, a feature flagging and experimentation platform that will tightly integrate with Datadog’s existing product analytics suite.

Cooley advised Chimerix (Nasdaq: CMRX), a biopharmaceutical company with a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, on its definitive agreement to be acquired by Jazz Pharmaceuticals (Nasdaq: JAZZ) for $8.55 per share in cash – totaling approximately $935 million.

Cooley advised Datadog (Nasdaq: DDOG), a monitoring and security platform for cloud applications, on its upsized $1 billion aggregate principal amount of 0% convertible senior notes due 2029, which includes the exercise in full of the initial purchasers’ option to purchase up to an additional $130 million aggregate principal amount of notes, a figure comprising an initial $870 million aggregate principal amount of notes and the exercise in full of the initial purchasers’ option to purchase up to an additional $130 million aggregate principal amount.